Canine Parvovirus Therapeutic Antibody Development

Canine Parvovirus (CPV) remains one of the most devastating viral infections affecting dogs worldwide, particularly puppies and immunocompromised animals. Despite vaccination efforts, severe outbreaks continue to occur due to viral mutation, incomplete immunity, or delayed vaccination schedules. At Creative Biolabs is advancing antibody-based therapeutics as a complementary or alternative strategy to vaccination, designed to provide rapid, potent, and specific protection against CPV infection. Our comprehensive service platforms enable the full development cycle of canine parvovirus neutralizing antibodies, from discovery to preclinical validation, accelerating veterinary innovation in infectious disease management.

Platforms in Therapeutic Antibody Discovery

Creative Biolabs integrates cutting-edge discovery technologies tailored for canine antibody R&D, offering an efficient and species-specific path toward CPV therapeutic antibody generation.

• Phage Display: Our phage display libraries are built on canine antibody repertoires to identify high-affinity, species-matched neutralizing antibodies targeting the CPV capsid proteins (VP1/VP2). This approach ensures reduced immunogenicity and improved in vivo performance in dogs.
• Single-B Cell Sorting: We isolate and analyze B cells from immunized or naturally infected canines to discover potent antibodies that neutralize diverse CPV strains. These murine-derived leads can then be engineered into fully canine antibodies for therapeutic development.
• Hybridoma Technology: Our hybridoma platform enables the generation of monoclonal antibodies from immunized hosts for downstream engineering, affinity maturation, and characterization, supporting robust candidate identification.

Comprehensive Antibody Development Services

Creative Biolabs offers a full spectrum of antibody R&D services that streamline canine therapeutic development pipelines.

Antibody Characterization

We conduct detailed functional analyses including binding affinity, epitope mapping, and viral neutralization assays against multiple CPV variants.

Antibody Engineering

Antibodies can be species-adapted, affinity-optimized, and engineered for enhanced stability or effector function tailored to canine immune systems.

Preclinical Evaluation

Our in vitro neutralization and canine infection model studies assess antiviral efficacy, safety, and pharmacokinetics.

Antibody Development

From early discovery to pilot-scale production, our team provides comprehensive development services, ensuring smooth progression to preclinical readiness.

Discover How We Can Help - Request a Consultation

Why Focus on Canine Parvovirus?

Canine Parvovirus is a highly contagious, non-enveloped DNA virus that primarily targets rapidly dividing cells in the intestinal crypts and bone marrow. It leads to severe hemorrhagic gastroenteritis, immunosuppression, and high mortality in young dogs. Despite the availability of vaccines, maternal antibody interference and viral antigenic variation can compromise protective immunity. Therapeutic antibodies targeting CPV capsid proteins offer immediate passive immunity, capable of neutralizing circulating virus and preventing systemic infection. Such biologics can serve as emergency treatments or as adjuncts in outbreak management, especially for unvaccinated or high-risk dogs.

Mechanism of Action

CPV-targeting antibodies function primarily through virus neutralization, binding to epitopes on the viral capsid proteins (VP1/VP2) and preventing viral attachment to the canine transferrin receptor (TfR), which is required for host cell entry. By blocking this critical step, the antibodies inhibit viral internalization and replication in the intestinal and hematopoietic tissues. Additionally, Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation, contribute to viral clearance. This dual mechanism enables therapeutic antibodies to both prevent infection and mitigate disease severity when administered post-exposure.

Fig 1. A Kaplan-Meier survival curve shows control group and canine parvovirus monoclonal antibody (CPMA) treatment group.¹

Our Advantages

• Veterinary-Specific Expertise: Deep experience in canine immunology and infectious disease therapeutics ensures that each antibody is optimized for species compatibility and efficacy.
• Comprehensive Development Pipeline: From antigen design to in vivo efficacy assessment, we provide complete R&D integration to accelerate development timelines.
• Advanced Neutralization Testing: Specialized in vitro and in vivo models for CPV evaluation deliver reliable data for decision-making.
• Collaborative Partnership Approach: We offer transparent communication, scientific flexibility, and customized project support for every client.

Partner with Creative Biolabs

As emerging viral strains challenge existing preventive measures, therapeutic antibodies represent a powerful tool for protecting canine health. Creative Biolabs provides the scientific infrastructure, expertise, and innovation required to bring CPV-targeted antibody therapies from concept to preclinical readiness. Whether your goal is to develop a rapid neutralizing antibody for clinical application or an experimental biologic for research use, our team is ready to collaborate.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Larson, Laurie, et al. "Early administration of canine parvovirus monoclonal antibody prevented mortality after experimental challenge." Journal of the American Veterinary Medical Association 262.4 (2024): 506-512. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.2460/javma.23.09.0541